The main objective of the study is to compare the maternal, fetal, and infant outcomes of pregnant women who are exposed to vonoprazan during pregnancy with outcomes of an internal comparison cohort of pregnant women who are unexposed to vonoprazan during pregnancy but who may be exposed to other products for the treatment of conditions for which vonoprazan may be prescribed.

Inclusion Criteria:

• Women 15 to 50 years of age.
• Currently or recently pregnant.
• Consent to participate.
• Authorization for her health care provider(s) (HCP[s]) to provide data to the registry.
• Exposed cohort: Exposure to at least one dose of vonoprazan during pregnancy.
• Unexposed cohort: Unexposed to vonoprazan and diagnosis of any condition for which vonoprazan may be prescribed.

Exclusion Criteria:

• Occurrence of pregnancy outcome prior to first contact with the virtual research coordination center (VRCC) (retrospectively enrolled).
• Exposure to known tetratogens and/or investigational medications during pregnancy.
• Lost to follow-up.

The study aims to enroll a total of 728 pregnant women in the study population from the United States, with 364 women in each cohort. This sample size will afford the study the ability to detect a 3-fold increase in the prevalence of the primary outcome, MCM, in the exposed cohort with 80% power.